BIO
HealthcareBio-Rad Laboratories, Inc. · Medical - Devices · $8B
What is Bio-Rad Laboratories, Inc.?
Bio-Rad Laboratories is a mid-cap healthcare company that develops and distributes life science research tools and clinical diagnostic products across global markets.
Bio-Rad operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment supplies reagents, instruments, and laboratory apparatus for research in genomics, proteomics, and food safety. The Clinical Diagnostics segment provides test systems, quality controls, and informatics software to hospital and reference laboratories worldwide.
Founded in 1980 and headquartered in Hercules, California.
- Life science research reagents and instruments
- Clinical diagnostic test systems and kits
- Quality controls for clinical laboratories
- Food safety testing solutions
Is BIO a Good Stock to Buy?
UQS Score rates BIO as Below Average overall.
The Risk and Valuation pillars are the relative bright spots in Bio-Rad's profile, suggesting the stock does not carry excessive financial risk and may not be priced at a premium relative to its fundamentals.
The Moat and Growth pillars both register as Weak, pointing to limited competitive differentiation and sluggish business expansion at this time.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BIO pay dividends?
No — Bio-Rad Laboratories, Inc. does not currently pay a dividend.
Bio-Rad does not currently pay a dividend. Capital is retained and directed toward research, product development, and operational needs — a common approach for life science companies prioritizing reinvestment over income distribution.
When does BIO report earnings?
Bio-Rad Laboratories reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue trends across both the Life Science and Clinical Diagnostics segments reflect the broader pressures facing the life science tools industry. Growth has been subdued relative to prior periods, consistent with the Weak Growth pillar label in the UQS framework.
For the most recent quarter's results, visit Bio-Rad Laboratories' investor relations page directly.
BIO Price History
-49.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Bio-Rad Laboratories, Inc.?
Based on Bio-Rad Laboratories, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Bio-Rad Laboratories do?
Bio-Rad manufactures and distributes life science research tools and clinical diagnostic products. Its two segments serve universities, pharmaceutical companies, biotechnology researchers, hospital laboratories, and food testing facilities across the United States, Europe, Asia, and Latin America.
Does BIO pay dividends?
No, Bio-Rad Laboratories does not pay a dividend. The company retains earnings for reinvestment into its research and product development activities rather than distributing cash to shareholders.
When does BIO report earnings?
Bio-Rad reports on a quarterly basis. Specific upcoming dates are not confirmed through our data source, so check the company's investor relations page for the current earnings calendar.
Is BIO a good stock to buy?
UQS Score rates BIO as Below Average. The Risk and Valuation pillars offer some support, but Weak readings on Moat and Growth indicate meaningful challenges. The complete pillar breakdown is available to Pro members.
Is BIO overvalued?
The UQS Valuation pillar for BIO is rated Good, suggesting the stock does not appear significantly overpriced relative to its fundamentals. Full valuation metrics are available inside the Pro dashboard.
What is BIO's market cap bracket?
Bio-Rad Laboratories is classified as a mid-cap company, placing it between smaller niche diagnostics players and large diversified healthcare conglomerates in terms of overall market size.
Is BIO a long-term quality stock?
As a long-term quality indicator, BIO's Below Average UQS Score reflects current weaknesses in moat and growth. Investors focused on long-term compounding may want to monitor whether these pillars improve before committing capital.
What sector does BIO belong to?
Bio-Rad Laboratories operates in the Healthcare sector, specifically within life science tools and clinical diagnostics — a segment that serves both research institutions and hospital laboratory networks globally.
Unlock Full BIO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access full financial metrics and historical trends
- ✓Compare BIO against sector peers on a standardized scoring framework
- ✓Get the complete analyst view available only to Pro members
Pro Analysis
BIO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 34.1 | 30.2 | 35.0 | 20.2 | 51.9 | 40.0 | 0.0 |
| May 22, 2026 | 34.1 | 30.2 | 35.0 | 20.2 | 51.9 | 40.1 | -0.1 |
| May 21, 2026 | 34.2 | 30.2 | 35.0 | 20.3 | 51.9 | 40.1 | -0.1 |
| May 19, 2026 | 34.3 | 30.2 | 35.0 | 20.3 | 51.9 | 40.7 | -0.5 |
| May 16, 2026 | 34.8 | 30.2 | 35.0 | 20.3 | 51.9 | 44.3 | -0.1 |
| May 15, 2026 | 34.9 | 30.2 | 35.0 | 20.4 | 51.9 | 44.9 | -0.1 |
| May 14, 2026 | 35.0 | 30.2 | 35.0 | 20.4 | 51.9 | 45.2 | +0.1 |
| May 13, 2026 | 34.9 | 29.7 | 35.0 | 20.4 | 51.9 | 45.4 | +0.1 |
| May 12, 2026 | 34.8 | 29.7 | 35.0 | 20.4 | 51.9 | 45.2 | +0.2 |
| May 11, 2026 | 34.6 | 29.7 | 35.0 | 20.4 | 51.9 | 43.9 | +3.0 |
BIO — Pillar Breakdown
Quality
— 30.2/100 (25%)Bio-Rad Laboratories, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 20.2/100 (20%)Bio-Rad Laboratories, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 51.9/100 (15%)Bio-Rad Laboratories, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 40.0/100 (15%)Bio-Rad Laboratories, Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 35/100 (25%)Bio-Rad Laboratories, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BIO.
Score Composition
Financial Data
More Stock Analysis
How is the BIO UQS Score Calculated?
The UQS (Unified Quality Score) for Bio-Rad Laboratories, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Bio-Rad Laboratories, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Bio-Rad Laboratories, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.